Amphotericin B represents one of the most important drugs available for antifungal therapy especially in the compromised patient. Unfortunately its administration presents many infusion-related or infusion-unrelated adverse effects, which are less frequent (but not absent) in patients receiving lipid-based formulations of amphotericin B. The present paper represents a summary of the prophylactic and therapeutic options available to manage amphotericin B related adverse events.
|Translated title of the contribution||Management of amphotericin B-related adverse events|
|Number of pages||5|
|Journal||Giornale Italiano di Malattie Infettive|
|Publication status||Published - 1999|
ASJC Scopus subject areas
- Microbiology (medical)